"Cardiomyopathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Descriptor ID |
D009202
|
| MeSH Number(s) |
C14.280.238
|
| Concept/Terms |
Cardiomyopathies- Cardiomyopathies
- Cardiomyopathy
- Myocardial Diseases
- Disease, Myocardial
- Diseases, Myocardial
- Myocardial Disease
- Myocardiopathies
- Myocardiopathy
Cardiomyopathies, Secondary- Cardiomyopathies, Secondary
- Cardiomyopathy, Secondary
- Secondary Cardiomyopathies
- Secondary Cardiomyopathy
- Secondary Myocardial Diseases
- Disease, Secondary Myocardial
- Diseases, Secondary Myocardial
- Myocardial Disease, Secondary
- Secondary Myocardial Disease
- Myocardial Diseases, Secondary
Cardiomyopathies, Primary- Cardiomyopathies, Primary
- Cardiomyopathy, Primary
- Primary Cardiomyopathies
- Primary Cardiomyopathy
- Primary Myocardial Diseases
- Myocardial Diseases, Primary
- Disease, Primary Myocardial
- Diseases, Primary Myocardial
- Myocardial Disease, Primary
- Primary Myocardial Disease
|
Below are MeSH descriptors whose meaning is more general than "Cardiomyopathies".
Below are MeSH descriptors whose meaning is more specific than "Cardiomyopathies".
This graph shows the total number of publications written about "Cardiomyopathies" by people in this website by year, and whether "Cardiomyopathies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 2 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 2 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 3 | 0 | 3 |
| 2009 | 4 | 1 | 5 |
| 2010 | 3 | 1 | 4 |
| 2011 | 7 | 2 | 9 |
| 2012 | 6 | 3 | 9 |
| 2013 | 5 | 3 | 8 |
| 2014 | 10 | 2 | 12 |
| 2015 | 7 | 3 | 10 |
| 2016 | 6 | 3 | 9 |
| 2017 | 13 | 1 | 14 |
| 2018 | 13 | 1 | 14 |
| 2019 | 3 | 0 | 3 |
| 2020 | 9 | 2 | 11 |
| 2021 | 7 | 0 | 7 |
| 2022 | 15 | 0 | 15 |
| 2023 | 17 | 0 | 17 |
| 2024 | 10 | 5 | 15 |
| 2025 | 10 | 0 | 10 |
| 2026 | 11 | 0 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiomyopathies" by people in Profiles.
-
Incremental prognostic value of cardiac magnetic resonance beyond biomarker staging in transthyretin cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2026 Sep 01; 27(9):1603-1612.
-
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B. J Am Coll Cardiol. 2026 Sep 22; 88(12):1402-1412.
-
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial. J Am Heart Assoc. 2026 Oct 06; 15(19):e050566.
-
Generation of two homozygous iPSC lines carrying variants of uncertain significance in LMNA associated with cardiomyopathy. Stem Cell Res. 2026 Sep; 95:104086.
-
Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection. Circ Cardiovasc Imaging. 2026 Jun; 19(6):e019610.
-
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. 2026 05 01; 11(5):446-454.
-
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. J Card Fail. 2026 May; 32(5):864-876.
-
Interventions and Perinatal Outcomes Associated With Recipient Twin Cardiomyopathy in the Setting of Twin-To-Twin Transfusion Syndrome: A Systematic Review. Prenat Diagn. 2026 Jul; 46(8):1159-1172.
-
Social Determinants of Health and Outcomes in Transthyretin Amyloid Cardiomyopathy. Am J Cardiol. 2026 06 15; 269:10-18.
-
Acoramidis in transthyretin amyloid cardiomyopathy: expanding evidence from ATTRibute-CM. Future Cardiol. 2026 02; 22(2):119-133.